الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 218 |  |  |
| | | from | 218 | | |
Abstract
Patients with hematologic malignancies are immunocompromised, frequent blood transfusion recepients and 1. V. drug users, so they are more prone to infections and epidemics of blood born hepatitis. NoW, hepatitis C virus is identified, and considered a major cause of post _transfusion and community aquired hepatitis. Our objective in the study was to detennine the prevalence ofHCV among hematologic malignancy patieuts, and to study the role of HCV being involved in the pathogensis ofNHL. This study comprised 100 patients with hematologic malignancies and 45 healthy volunteer blood donors. Patients with hematologic malignancies were categorized into 6 groups: group I (NHL patients), group II (lID patients), _ group III (ALL patients), group IV (AML patients) group V (CML patients), and group VI (CLL patients). All patients were subjected to full history taking, thorough physical examination and laboratory investigations including: investigations to diagnose the hematologic malignancy, liver fuction tests, HBsAg, HBclgM, HBclgG, Anti-HCV antibody test (ELISA II), and PCR (for 10 anti-HCV positive) patients. The present study demonstrates a high prevalence of a HCV among patients with hematologic malignancies (44%) that is significantly higher than in the control group (28.9%). The high prevalence of anti-HCV in our patients was not explained by blood transfusion, surgical operation or cancer chemotherapy Suggesting an additional and even more